Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 78 of 78 results for psoriasis

  1. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

    Technology appraisal guidance
    Published
    1 February 2016
    View recommendations

    Sections for TA383

  2. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

    Technology appraisal guidance
    Published
    6 December 2023
    View recommendations

    Sections for TA935

  3. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

    Medtech innovation briefing
    Published
    1 November 2022